All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): FAP-Activated Doxorubicin prodrug
Therapeutic Area: Oncology Product Name: AVA6000
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 18, 2021
Details:
In AVA6000, doxorubicin has been modified with Avacta’s pre|CISIONTM chemistry, which renders the modified drug inactive in the circulation until it enters the tumour micro-environment.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sulforaphane,Alpha-Cyclodextrin
Therapeutic Area: Oncology Product Name: SFX-01
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $15.3 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 02, 2021
Details:
The net proceeds of the Fundraising are intended to be used to complete the formulation and scale up manufacturing of SFX-01 and other R&D nd general corporate purposes.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sulforaphane
Therapeutic Area: Oncology Product Name: SFX-01
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 21, 2021
Details:
The data generated for SFX-01 in standard pre-clinical models and orthotopic models (where glioma cells are implanted in brain tissue representing a more disease-relevant model) show tumour shrinkage and significantly extended survival times.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Pro-doxorubicin
Therapeutic Area: Oncology Product Name: AVA6000
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Point Biopharma
Deal Size: $17.5 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 07, 2021
Details:
The agreement provides POINT with an exclusive license to the pre|CISION technology for use AVA6000 Pro-doxorubicin the company intends to develop, and a non-exclusive license to the pre|CISION™ platform to develop broader pipeline of FAP-activated radiopharmaceuticals.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): FAP activated doxorubicin prodrug
Therapeutic Area: Oncology Product Name: AVA6000
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 23, 2020
Details:
The dose-escalation phase of the study, which will be carried out in 15-20 patients, is designed to evaluate the safety of AVA6000 in humans and establish the appropriate dosing levels for the dose expansion phase of the study.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
